Cover Image

Biochemical recurrence of prostate cancer: initial results with (18F)PSMA-1007 PET/CT

Biochemical recurrence (BCR) is a concern for prostate cancer patients after local treatment. 68Ga-labeled prostate-specific membrane antigen (PSMA) ligands have significantly improved prostate cancer imaging. However, several 18F-labeled ligands that were developed as fluorinated tracers might pres...

Full description

Saved in:
Bibliographic Details
Main Authors: Giesel, Frederik L. (Author) , Will, Leon (Author) , Kesch, Claudia (Author) , Freitag, Martin T. (Author) , Kremer, Christophe (Author) , Merkle, Jonas (Author) , Kiß, Oliver (Author) , Cardinale, Jens (Author) , Hadaschik, Boris (Author) , Hohenfellner, Markus (Author) , Kopka, Klaus (Author) , Haberkorn, Uwe (Author) , Kratochwil, Clemens (Author)
Format: Article (Journal)
Language:English
Published: Feb. 1, 2018
In: Journal of nuclear medicine
Year: 2018, Volume: 59, Issue: 4, Pages: 632-635
ISSN:2159-662X
DOI:10.2967/jnumed.117.196329
Online Access:Verlag, Volltext: https://doi.org/10.2967/jnumed.117.196329
Verlag, Volltext: http://jnm.snmjournals.org/content/59/4/632
Get full text
Author Notes:Frederik L. Giesel, Leon Will, Claudia Kesch, Martin Freitag, Christophe Kremer, Jonas Merkle, Oliver C. Neels, Jens Cardinale, Boris Hadaschik, Markus Hohenfellner, Klaus Kopka, Uwe Haberkorn, and Clemens Kratochwil
Description
Summary:Biochemical recurrence (BCR) is a concern for prostate cancer patients after local treatment. 68Ga-labeled prostate-specific membrane antigen (PSMA) ligands have significantly improved prostate cancer imaging. However, several 18F-labeled ligands that were developed as fluorinated tracers might present advantages. In this study, we analyzed the potential of 18F-PSMA-1007 in patients with BCR. Methods: Twelve patients with BCR after local treatment underwent PET/CT scans 1 and 3 h after injection of 18F-PSMA-1007. Results: 18F-PSMA-1007 PET/CT detected lesions in 9 of 12 patients (75%). A significant difference was observed when comparing the tracer uptake in 18F-PSMA-1007-positive lesions 1 and 3 h after injection (median SUVmax, 7.00 vs. 11.34; P < 0.001; n = 76). Forty-four (88%) of 50 18F-PSMA-1007-positive lymph nodes had a short-axis diameter of less than 8 mm. Conclusion: In this pilot study, 18F-PSMA-1007 PET/CT presented high potential for localization of recurrent disease in prostate cancer patients with BCR.
Item Description:Gesehen am 05.04.2019
Die Zahl "18" ist im Titelzusatz hochgestellt
Physical Description:Online Resource
ISSN:2159-662X
DOI:10.2967/jnumed.117.196329

Similar Items